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Summary 
Discovery and validation of a three-gene blood transcription signature for incipient tuberculosis and 
its application for stratification of risk of disease in HIV negative contacts of active tuberculosis. 
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Abstract 
Background 
The highest risk of tuberculosis (TB) arises in the first few months after exposure. We reasoned that 
this risk reflects incipient disease among TB contacts. Blood transcriptional biomarkers of TB may 
predate clinical diagnosis, suggesting they offer improved sensitivity to detect subclinical incipient 
disease. Therefore, we sought to test the hypothesis that refined blood transcriptional biomarkers of 
active TB will improve stratification of short-term disease risk in TB contacts. 
Methods 
We combined analysis of previously published blood transcriptomic data with new data from a 
prospective HIV negative United Kingdom cohort of 333 TB contacts. We used stability selection as 
an alternative computational approach to identify an optimal signature for short-term risk of active 
TB, and evaluated its predictive value in independent cohorts. 
Results 
In a previously published HIV negative South African case-control study of patients with 
asymptomatic Mycobacterium tuberculosis infection, a novel three-gene transcriptional signature 
comprising BATF2, GBP5 and SCARF1 achieved a positive predictive value (PPV) of 23% for 
progression to active TB within 90 days. In a new UK cohort of 333 HIV negative TB contacts with a 
median follow up of 346 days, this signature achieved a PPV of 50% (95% confidence interval: 15.7-
84.3) and NPV of 99.3% (97.5-99.9). By comparison, peripheral blood interferon gamma release 
assays in the same cohort achieved a PPV of 5.6% (2.1-11.8). 
Conclusion 
This blood transcriptional signature provides unprecedented opportunities to target therapy among 
TB contacts with greatest risk of incident disease. 
Keywords 
Blood transcriptome; biomarker; tuberculosis; diagnosis. 
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Introduction 
The causative agent of tuberculosis, Mycobacterium tuberculosis (Mtb) is an obligate pathogen [1]. In 
the absence of an effective vaccine, the earliest possible identification of disease offers the best 
strategy to reduce onward transmission. Early treatment also offers the opportunity to adopt shorter 
and simpler treatment regimens, to limit pathology and reduce TB-associated morbidity. This 
rationale, and the fact that risk of TB is highest within the first few months after significant exposure 
[2,3] provide the basis for screening close contacts of patients with active TB, in order to identify 
prevalent disease and offer preventative treatment to individuals with asymptomatic infection. 
Detection of immune memory for Mtb, using interferon gamma release assays (IGRA) or the 
tuberculin skin test (TST), is widely used to identify infected individuals. These tests have poor 
sensitivity, estimated as 50-85% for identifying contacts who progress to TB. In addition, they have 
poor positive predictive value (PPV), estimated to be <5% for two-year cumulative TB incidence or 
1-1.5 per 100 person years [4–6]. In the absence of clinical disease, the ability to stratify differential 
risk of progression to TB remains extremely limited, leading to unnecessary treatment of people at 
low risk. The fact that overall risk is low means that significant numbers of individuals refuse the offer 
of treatment, thereby undermining the overall effectiveness of contact tracing to prevent incident 
TB. 
Blood transcriptomic biomarkers have emerged as a sensitive approach for identification of active TB 
[7–11]. Importantly, these may predate conventional clinical diagnosis [12,13]. In a South African 
cohort of HIV negative individuals with latent TB infection [12], the sensitivity of a 16-gene blood 
transcriptional signature that discriminated individuals who progressed to a diagnosis of active TB 
from those who did not, improved as the time interval between sampling and diagnosis reduced. 
These data suggest that blood transcriptional signatures can identify pre-symptomatic incipient 
disease. The fact that blood transcriptional changes may not be suitable for stratification of 
long-term risk was highlighted in a second multi-cohort African study of house-hold contacts that 
specifically excluded patients who progressed to active TB within three months of enrolment [13]. In 
that study, a four-gene blood transcriptional signature discriminated between progressors and 
non-progressors with only modest receiver operating characteristic area under the curve (AUC) of 
0.69 and positive predictive value (PPV) of 3%, equivalent to that of IGRAs or TST. 
These studies focussed on deriving blood transcriptional signatures for prospective risk of incident TB 
for up to two years. However, they may not represent the most sensitive biomarkers of preclinical 
incipient disease underlying the short-term risk of TB amongst contacts. We recently reported that 
BATF2 gene expression provided a single blood transcript that accurately discriminated active from 
latent TB infection [11]. BATF2 was identified by comparing transcriptional profiles from patients 
with active and treated TB. Of note, BATF2 is a component of the 16-gene signature reported by Zak 
et al [12]. In the present study we tested the ability of BATF2 on its own, to identify incipient TB 
disease in the Zak cohort. In addition, we sought to improve on the predictive value of BATF2, using 
stability selection as an alternative computational approach to identifying discriminating features in 
high dimensional data. We then validated our findings in two independent data sets. First, the 
previously published South African cohort of HIV negative individuals with latent TB infection [12] 
and then a new UK cohort of TB contacts. 
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Methods 
Analysis of previously published data 
Raw sequencing data from Zak et al [12] was pseudoaligned to the human transcriptome (Ensembl 
Human GRCh38) using Kallisto [14]. The abundance for protein coding RNA was expressed as 
log2-transformed transcripts per million (TPM) [15]. Microarray data from Roe et al [11] were used as 
normalised log2-transformed data. RNAseq and microarray data were standardised by subtracting 
the mean and dividing by the standard deviation of each data set. Gene expression data from each 
study were annotated with Human Genome Organisation Nomenclature Committee (HGNC) gene 
symbols. 
Blood transcriptional profiling of a UK cohort of TB contacts. 
Close contacts of patients with TB were invited to participate (Supplementary methods). The study 
was approved by the UK National Research Ethics Service (reference: 14/EM/1208). All participants 
provided written informed consent. At enrolment, IGRAs were done using the QuantiFERON-TB Plus 
assay (Qiagen, Germany), and peripheral blood RNA was collected into TempusTM tubes for 
transcriptional profiling by RNA sequencing (Supplementary methods). These data are available in 
ArrayExpress (https://www.ebi.ac.uk/arrayexpress/) under the accession number E-MTAB-6845. At 
the end of the study, participants who progressed to active TB were identified by linkage with the 
national electronic TB register as previously described [17]. Local case notes were reviewed in order 
to identify individuals who had received preventative treatment. 
Stability selection to refine the optimal gene signature for incipient TB. 
We combined stability selection with Support Vector Machines (SVM) [18] (Supplementary 
methods), to identify a ranking of the individual transcripts independent of other genes, which 
discriminated patients with active TB pre-treatment from those who had been successfully treated 
[11]. Once we had selected a consistent sub-set of discriminating genes using stability selection, we 
used these genes to train a traditional L2 Norm learning SVM using kernlab with a linear kernel in the 
R statistical computing platform [19] as previously described [11]. We used this SVM to generate 
decision values for each data set tested. ROC curves were plotted in GraphPad Prism version 7 
(GraphPad Software, La Jolla, California, USA) and used to calculate the ROC AUC. The Youden Index 
for each ROC curve was derived from the sum of sensitivity and specificity–1 [20], and the predictive 
value of each transcriptional signature was estimated using Bayesian conditional probabilities [21]. 
95% confidence intervals are provided for each measure of test performance. 
Results 
Positive predictive value of BATF2 blood transcript levels for short-term risk of incident TB. 
We first sought to test the hypothesis that elevated blood levels of BATF2 gene expression identified 
individuals with subclinical incipient disease leading to incident TB in the short-term. We compared 
BATF2 blood transcript levels in all samples from individuals with latent TB in the Zak cohort [12], 
who did not progress to active TB (N=48), with samples from individuals who progressed to active TB 
within 90 days (N=12), 91-360 days (N=29), and after an interval of greater 360 days (N=25). In this 
analysis, we ensured that samples were not incorrectly allocated to the non-progressor group 
because of inadequate follow up, by restricting the non-progressor group to include only samples 
from individuals who had more than 12 months follow up after sample was collected. Consistent 
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with our hypothesis, BATF2 blood transcript levels were highest in the group of individuals who 
progressed to active TB within 90 days (Figure 1A). Accordingly, discrimination of individuals who 
progress to TB from non-progressors using BATF2 levels, achieved the highest ROC AUC of 0.93 (0.86-
1) in the group who progressed to TB within 90 days (Figure 1B). The threshold for BATF2 levels 
which discriminated this group of progressors from non-progressors with the greatest accuracy was 
identified by the ROC curve Youden index. This threshold achieved a sensitivity of 0.83 (0.52-0.98) 
and specificity of 0.92 (0.83-0.99) (Figure 1C), giving a positive likelihood ratio of 13.3 (4.3-41.1). At 
the same threshold, the sensitivity of elevated BATF2 levels to identify individuals who progressed to 
TB after 90 days was reduced to 0.52 (0.36-0.74), in the 91-360 days interval, and to 0.24 (0.12-0.49) 
after 360 days. The cumulative TB risk in this cohort approximated to 1.5% [12]. Using this pre-test 
probability, we estimated the PPV of elevated BATF2 levels for diagnosis of TB within 90 days to be 
13% (Figure 1C). These were comparable to those of disease within 90 days using the 16-gene 
signature described by Zak et al, which achieved a ROC AUC of 0.94, (0.89-1) (Supplementary Figure 
1). 
A refined three-gene signature to predict active TB within 90 days. 
In the clinical cohort described by Zak et al, their 16-gene signature offered no advantage to 
measuring BATF2 transcripts alone to discriminate progressors within 90 days from non-progressors. 
Nonetheless, we hypothesised that the addition of selected genes may further improve the 
performance of BATF2 alone as a biomarker of incipient TB. We reasoned that the most 
discriminating transcriptional biomarker may be different among subsets of cases. Therefore, a 
combination of the genes most frequently ranked top in multiple subsamples of the data may give 
the optimal gene signature for incipient TB. This approach to feature selection in high dimensional 
data has been called stability selection [18]. We used stability selection to rank the transcripts that 
best discriminated subsets of our previously published active and treated TB cases [11]. Using this 
ranking, we trained an SVM model to discriminate active and treated TB with a cumulative number of 
genes and tested how accurately each SVM model correctly classified progressor and non-progressor 
patients in the Zak cohort (Supplementary Figure 2B). The most accurate classification was achieved 
by the top three genes comprising BATF2, GBP5 and SCARF1 (Supplementary Figure 2C). We 
represented the three-gene score for each individual in the Zak cohort, as the distance from the 
separating hyperplane that discriminates between two classes in the SVM model (Figure 2A). The 
three-gene SVM model discriminated between non-progressors and those who progressed to TB 
within 90 days with a ROC AUC of 0.96, (0.92-1) (Figure 2B). At the Youden Index, this ROC curve 
generated a sensitivity of 0.83 (0.52-0.98) and specificity of 0.96 (0.83-0.99). This was equivalent to a 
positive likelihood ratio of 20 (5-79.5) and a PPV for active TB within 90 days of 23%, given a prior 
probability of 1.5% (Figure 2C). 
Predictive value of the three-gene signature for active TB in a new UK cohort of TB contacts. 
The predictive value of a TB biosignature based on BATF2, GBP5 and SCARF1 described above was 
obtained from estimates of sensitivity, specificity derived from case-control data, and estimates of 
prior probability. A prospective, independent observational cohort was required to confirm these 
findings. In addition, although our three-gene signature was discovered in data derived from a UK 
cohort of patients with active TB and validated in a South African cohort of patients with latent TB, 
additional validation in a further independent UK cohort at risk of active TB was necessary to extend 
the evidence for its generalisability. Therefore, we obtained blood transcriptomic data from a new 
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observational HIV negative cohort of 333 close contacts of cases of active TB, representing a group at 
highest risk of developing disease in the short-term (Table 1). Median follow-up of the cohort was 
346 days (IQR: 250-450). A total of 6 participants in the cohort progressed to a diagnosis of TB 
disease 3-342 days after recruitment to the study (Table 2). 
We used the novel three-gene model to calculate a decision score as described above, for each 
patient in the UK TB contacts cohort. First, we sought to define the distribution of three-gene scores 
in 192 IGRA negative contacts as a control population among TB contacts with low risk of developing 
disease. This group was younger, had fewer non-UK born individuals and fewer household contacts 
of TB, compared to the IGRA positive individuals, reflecting known risk factors for acquisition of Mtb 
infection (Table 1). The three-gene scores among the IGRA negative group showed a parametric 
distribution. Therefore, we used standard score of two (Z2) to represent the 97.7
th percentile, and 
three (Z3) to represent the 99.9
th percentile as thresholds for an elevated three gene score (Figure 
3A). We then compared the distribution of three-gene scores among all the IGRA positive contacts, 
and tested the hypothesis that the three-gene score stratifies differential risk of incident TB in this 
cohort. Among individuals in the cohort who did not receive preventative therapy, we compared the 
incident TB rate per 100 person years in all IGRA positive and IGRA negative contacts with three-gene 
scores greater than the Z2 and Z3 thresholds (Figure 3B). 
Using the Z2 threshold, TB incidence rate among individuals with a low three-gene score was 0.76 per 
100 person years (0.19-3.05). Among 19 individuals with a high three-gene score, the TB incidence 
rate was 27.7 per 100 person years (10.4-73.8). The incidence rate ratio (incidence of TB for those 
with a high three-gene score compared to those with a low three-gene score) was 36.3 (6.6-198.1). 
Using the Z3 threshold, TB incidence rate among individuals with a low three-gene score was 0.74 per 
100 person years (0.18-3.0). Among 8 individuals with a high three-gene score, the TB incidence rate 
was 72.0 per 100 person years (27.0-191.8). The incidence rate ratio (incidence of TB for those with a 
high three-gene score compared to those with a low three-gene score) was 97.4 (17.8-532.0). By 
comparison, incidence rates were 5.8 per 100 person years (2.6-13.0) and 0 per 100 person years 
among IGRA-positive and -negative contacts, respectively. Overall, at the Z2 threshold, the 
three-gene score achieved a PPV of 21.1% (6.1-46.6), and positive likelihood ratio of 13 (6.2-27.6). At 
the Z3 threshold, the three-gene score achieved a PPV of 50% (15.7-84.3), and positive likelihood 
ratio of 48.8 (15.8-150.5). Both these thresholds for the three-gene score achieved NPV of 99.3% 
(97.5-99.9 for the Z3 threshold and 97.4-99.9 for the Z2 threshold), and negative likelihood ratio of 
0.35 (0.11-1.1) for cumulative incident TB within two years. The IGRA result achieved a PPV of 5.6% 
(2.1-11.8) and an NPV of 100% (98.1-100). 
Discussion 
The present study was based on the premise that blood transcriptional biomarkers of active TB 
predate clinical presentation of disease and consequently serve as biomarkers of incipient TB. We 
confirmed this hypothesis in data from a South African case-control study, using a single 
transcriptional biomarker for active TB, BATF2. The addition of two further genes generated a 
three-gene signature derived from independent data, which further enhanced the discrimination 
between short-term progressors and non-progressors in the case-control study. Finally, we validated 
our findings in a new UK cohort study.  
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We provide the first proof of concept data for a blood transcriptional signature that predicts the 
short-term risk of disease in TB contacts with substantially greater PPV than is achieved in current 
practice using IGRAs. The three-gene signature in the present study was derived from comparison of 
patients with pulmonary TB before and after treatment, but predicted cases of extrapulmonary 
disease in the UK cohort, consistent with the hypothesis that blood transcriptional signatures of TB 
are not specific to different sites of disease. Our blood transcriptional signature predicted disease 
progression in four of six close contacts. The patient who progressed within three days, was 
symptomatic at enrolment, but the others had no symptoms of active disease, supporting the 
underlying hypothesis that this signature predates clinical presentation of disease. The potential 
clinical impact of this approach is to enable more precise targeting of preventative antimicrobial TB 
treatment. On the basis of the differential PPVs among contacts of active TB, risk stratification using 
the blood transcriptional signature may reduce the number needed to treat to <5, compared to >20 
using IGRAs. In addition, the better PPV of the blood transcriptional signature may be expected to 
incentivise increased treatment acceptance and completion rates. Taken together, these effects have 
the potential to transform the efficiency and therefore scalability of contact tracing as part of a TB 
control program.  
In the South African case-control study, the sensitivity of the three-gene signature to identify 
individuals who progressed to TB reduced as interval time to TB increased. Consistent with this, in 
the UK cohort study, the three-gene signature failed to identify two of six contacts that progressed to 
active TB, with the longest disease-free intervals, both greater than six months. These data highlight 
the reduced sensitivity for long-term risk of incident disease. Therefore, interval follow-up 
measurements for IGRA positive contacts may be needed to prevent cases beyond the first six 
months. Thereafter the numbers needed to screen and treat with preventative therapy for the very 
small residual long-term risk of disease, may not justify the economic cost and risk of drug toxicity. To 
illustrate this, in a large observational cohort of 4,861 TB contacts with median follow-up 2.9 years, 
52% and 73% of incident TB cases occurred within six and 12 months of contact screening, 
respectively [6]. Therefore, a strategy of testing recent TB contacts with blood transcriptional 
biomarkers at baseline and after a six-month interval may identify up to three quarters of incident TB 
cases among contacts. 
The major limitation of our study is the low frequency of progressive disease in the UK cohort. 
Despite the fact that TB contacts have the highest short-term risk of disease, the absolute two-year 
cumulative incidence of disease is low, necessitating very large scale cohorts to definitively assess the 
correlates of progression [6]. Consequently, in the present study, the confidence intervals of the PPV 
for the three-gene signature are wide, albeit significantly better than IGRA which achieves a PPV of 
<5% in large scale studies. The impact of HIV co-infection is also untested. In addition, it is clear that 
a high three-gene score is evident in individuals who do not develop active TB. This observation may 
reflect spontaneous resolution of subclinical TB among some individuals, inadequate follow up of 
these patients, or a lack of specificity for TB. Therefore, further assessments of potential confounding 
of this transcriptional signature by HIV co-infection, other co-morbidities and longitudinal studies of 
the expression of this signature with and without TB treatment are required. Notwithstanding these 
limitations, we propose that the three-gene blood transcriptional signature offers exciting new 
opportunities to transform risk stratification for progression to TB disease among contacts of active 
TB. This application of the blood transcriptional signature is consistent with proposals from the 
World Health Organisation for a non-sputum test with sensitivity and specificity of >75%, that 
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predicts risk of disease in patients with incipient TB [22]. Our findings pave the way for extended 
validation of the signature, “head to head” comparison of the performance of the different published 
blood transcriptional signatures of TB and development of the technology to allow scale-up of near-
patient testing.  
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Tables 
Table 1. Summary characteristics of UK TB contacts cohort 
  
All  
(n=333) 
IGRA +ve 
(n=141) 
IGRA –ve 
(n=192) 
P 
value 
Age  Median (IQR), years 33 (26-47) 40.5 (29-51) 32 (25-43) <0.05 
  
n % n % n %  
Gender 
Male 173 52.0 77 54.6 96 50.0 ns 
Female 155 46.5 62 44.0 93 48.4 ns 
NA 5 1.5 2 1.4 3 1.6 ns 
Ethnicity 
White 73 21.9 24 17.0 49 25.5 ns 
Indian, Pakistani or Bangladeshi 120 36.0 51 36.2 69 35.9 ns 
Black African 56 16.8 32 22.7 24 12.5 <0.05 
Mixed 64 19.2 29 20.6 35 18.2 ns 
Other 10 3.0 2 1.4 8 4.2 ns 
NA 10 3.0 3 2.1 7 3.6 ns 
Country of 
Birth 
Non-UK 259 77.8 126 89.4 133 69.3 <0.05 
UK 68 20.4 12 8.5 56 29.2 <0.05 
NA 6 1.8 3 2.1 3 1.6 ns 
TB contact 
type 
Household 218 65.5 103 73.0 115 59.9 <0.05 
Non-Household 77 23.1 25 17.7 52 27.1 <0.05 
NA 38 11.4 13 9.2 25 13.0 ns 
Social risk 
factor 
Yes 35 10.5 13 9.2 22 11.5 ns 
No 298 89.5 128 90.8 170 88.5 ns 
NA 0 0 0 0 0 0 ns 
Diabetes 
Yes 27 8.1 16 11.3 11 5.7 ns 
No 296 88.9 122 86.5 174 90.6 ns 
NA 10 3 3 2.1 7 3.6 ns 
Smoking 
Current 76 22.8 32 22.7 44 22.9 ns 
Previous 43 12.9 18 12.8 25 13 ns 
No 21. 63.1 89 63.1 121 63 ns 
NA 4 1.2 2 1.4 2 1 ns 
Preventative 
therapy 
Yes 34 10.2 34 24.1 0 0 n/a 
No 289 86.8 97 68.8 192 100 n/a 
NA 10 3.0 10 7.1 0 0 n/a 
Abbreviations: IQR- interquartile range; NA- not available; n/a- not applicable. For statistical tests, 
age was compared by a Mann Whitney U test and categorical variables were compared using Chi 
squared tests. Social risk factors included history of homelessness, imprisonment or harmful drug 
use.
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Table 2. Selected characteristics of patients who progressed to a diagnosis of TB in the UK cohort study 
Disease free 
interval (days) 
Age 
(years) 
Gender Ethnicity IGRA Site of disease Culture confirmed Symptoms at 
screening 
Screening chest radiograph 
3 32 Female Indian Positive Uterus Yes Yes Normal 
90 16 Male Black African Positive Pleural No No Normal 
137 21 Male Mixed Positive Lymph node No No Normal 
210 21 Female Mixed Positive Lymph node No No Paratracheal adenopathy 
272 52 Male Indian Positive Pleural Yes No Normal 
342 27 Female Black African Positive Pleural No No Normal 
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Figure Legends 
Figure 1 
Identification of incipient TB by measurement of blood BATF2 transcript levels. 
(A) BATF2 transcript levels (TPM) are shown for blood samples from all patients in the Zak cohort 
(with at least 12 months follow up after the time of sampling) who did not progress to TB (NP), and 
for samples from patients who progressed to a diagnosis of TB within the time intervals indicated. (B) 
Receiver operating characteristic (ROC) curves for discriminating between NP and progressors in 
each time interval shown using the BATF2 transcript level. (C) Positive predictive value for a diagnosis 
of TB (PPVTB) for patients who progress to TB within 90 days, using sensitivity and specificity values 
derived from the optimal Youden Index (dotted line in (A)) of the ROC curve in (B) and a range of 
pre-test (PT) probabilities. Arrows highlight the PPVTB of 13% for PT probability of 1.5%. 
Figure 2 
Identification of incipient TB by a novel 3-gene model incorporating blood transcript levels of 
BATF2, GBP5 and SCARF1. 
(A) Three-gene scores derived from the SVM model to discriminate between active and treated TB, 
are shown for blood samples from all patients in the Zak cohort (with at least 12 months follow up) 
who did not progress to TB (NP), and for samples from patients who progressed to a diagnosis of TB 
within the time intervals indicated. (B) ROC curves for discriminating between NP and progressors in 
each time interval shown using the three-gene scores. (C) Positive predictive value for a diagnosis of 
TB (PPVTB) for patients who progress to TB within 90 days, using sensitivity and specificity values 
derived from the optimal Youden Index of the ROC curve in (B) and a range of pre-test (PT) 
probabilities. Arrows highlight the PPVTB of 23% for PT probability of 1.5%.  
Figure 3 
Blood transcriptomic 3-gene score at recruitment in contacts of active TB. 
(A) Frequency distribution of 3-gene scores in IGRA negative contacts of active TB showing threshold 
(dashed lines) for identification of a high 3-gene score based on the mean+2 SD (Z2) or +3 SD (Z3) of 
the scores among IGRA negative cases. (B) Individual 3-gene scores for untreated IGRA positive and 
negative contacts who developed active TB or remained healthy on follow up. 
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